ライフサイエンスコーパス: peripheral artery

1 nt tissue loss and/or arterial thrombosis in peripheral arteries).

2 to atheromatous plaques in carotid or other peripheral arteries.

3 an important cardiovascular disorder of the peripheral arteries.

4 herosclerotic lesions occurs in coronary and peripheral arteries.

5 neointima formation in small animals and in peripheral arteries.

6 e primary sensor of intraluminal pressure in peripheral arteries.

7 sorption and distribution in cadaveric human peripheral arteries.

8 older age and occur similarly in central and peripheral arteries.

9 The carotid and peripheral arteries all have excellent short-term reprod

10 In humans, a high ABI indicates stiff peripheral arteries and is associated with cardiovascula

11 arge public university and participated in a peripheral artery and venous disease study.

12 but stimulated proliferation of PASMCs from peripheral arteries, and conferred protection from apopt

13 assed and stented vessels, carotid arteries, peripheral arteries, and the aorta.

14 progressive aortic dilation, dissection, and peripheral artery aneurysm after composite aortic graft

15 ured and the presence of dissection or major peripheral artery aneurysms was determined.

16 Endovascular interventions on peripheral arteries are limited by high rates of resteno

17 cted intravenously traveled rapidly down the peripheral arteries at approximately 6 seconds per stati

18 udy, restenotic segments taken from 30 human peripheral arteries by directional atherectomy at times

19 sequent vein graft failure after coronary or peripheral artery bypass grafting.

20 ular recanalization (guidewire traversal) of peripheral artery chronic total occlusion (CTO) can be c

21 ), persistent or recurrent manifestations of peripheral artery disease (22.2%), cardiac conditions (1

22 ER = $44,779/QALY gained), and patients with peripheral artery disease (ICER = $13,427/QALY gained).

23 d dipstick proteinuria with the incidence of peripheral artery disease (including hospitalisation wit

24 amputation in patients with lower-extremity peripheral artery disease (LE PAD) during the study peri

25 diameter is associated with lower-extremity peripheral artery disease (LE-PAD).

26 lled trial conducted among 212 patients with peripheral artery disease (mean age, 65.5 [SD, 6.2] year

27 ts with stable coronary, cerebrovascular, or peripheral artery disease (n = 15,264) had a lower risk

28 Patients with qualifying peripheral artery disease (n=3787) had a history of clau

29 s (odds ratio [OR]: 1.27; p = 6.7 x 10(-4)), peripheral artery disease (OR: 1.47; p = 2.9 x 10(-14)),

30 ARAS was associated with peripheral artery disease (p = 0.004) and lower high-den

31 than in controls without clinically evident peripheral artery disease (P<0.0001).

32 cco use is an important preventable cause of peripheral artery disease (PAD) and a major determinant

33 about the prevalence of objectively assessed peripheral artery disease (PAD) and its clinical relevan

34 Patients with peripheral artery disease (PAD) are at heightened risk o

35 Patients with peripheral artery disease (PAD) are at heightened risk o

36 Patients with peripheral artery disease (PAD) are at high risk of card

37 New data on the epidemiology of peripheral artery disease (PAD) are available, and they

38 ospective data pertaining to MetS and future peripheral artery disease (PAD) are sparse, with few stu

39 lking ability in people with lower extremity peripheral artery disease (PAD) are unclear.

40 cy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on

41 ioprotective medications in the treatment of peripheral artery disease (PAD) by socioeconomic status

42 The prevalence of peripheral artery disease (PAD) continues to increase wo

43 Peripheral artery disease (PAD) generates tissue ischemi

44 Many patients with peripheral artery disease (PAD) have walking impairment

45 Whether individuals with peripheral artery disease (PAD) identified by screening

46 To define how the incidence of peripheral artery disease (PAD) in chronic kidney diseas

47 mine whether there is a higher prevalence of peripheral artery disease (PAD) in individuals with lowe

48 se and lifestyle counseling in patients with peripheral artery disease (PAD) in the United States.

49 Peripheral artery disease (PAD) is associated with heigh

50 Peripheral artery disease (PAD) is associated with incre

51 Lower extremity peripheral artery disease (PAD) is frequently underdiagn

52 Screening for peripheral artery disease (PAD) may reduce morbidity and

53 reely perfused and ligated femoral arteries: peripheral artery disease (PAD) model.

54 t for claudication that is due to aortoiliac peripheral artery disease (PAD) often relies on stent re

55 ysis patients, but its effect on the risk of peripheral artery disease (PAD) remains unclear.

56 Patients with peripheral artery disease (PAD) show an exaggerated EPR,

57 t evidence to support advising patients with peripheral artery disease (PAD) to participate in a home

58 termine the association of family history of peripheral artery disease (PAD) with PAD prevalence and

59 by screening ankle brachial indices <0.9 for peripheral artery disease (PAD), and ultrasound imaging

60 shown by limb osteoporosis in patients with peripheral artery disease (PAD), but also could result f

61 ndividual clinical risk factors with risk of peripheral artery disease (PAD), but the combined effect

62 variance) to estimate prevalence ratios for peripheral artery disease (PAD), coronary artery calcifi

63 recommendations for secondary prevention in peripheral artery disease (PAD), the effect of aspirin i

64 Among persons with lower extremity peripheral artery disease (PAD), we determined whether o

65 effective treatment option for patients with peripheral artery disease (PAD).

66 long-term diabetes complications, including peripheral artery disease (PAD).

67 ngiogenic cytokine elevated in patients with peripheral artery disease (PAD).

68 ity among men and women with lower extremity peripheral artery disease (PAD).

69 oB) and lipoprotein (a) [Lp(a)], and risk of peripheral artery disease (PAD).

70 r challenge to intraluminal drug delivery in peripheral artery disease (PAD).

71 e 6-minute walk performance in patients with peripheral artery disease (PAD).

72 cular-weight (HMW) adiponectin, and incident peripheral artery disease (PAD).

73 cessation program designed for patients with peripheral artery disease (PAD).

74 cting the lower extremities is also known as peripheral artery disease (PAD).

75 or (VEGF) gene transfer for the treatment of peripheral artery disease (PAD).

76 rement in healthy subjects and subjects with peripheral artery disease (PAD).

77 d improving outcomes in patients with severe peripheral artery disease (PAD).

78 sed revascularization rates in patients with peripheral artery disease (PAD).

79 ve pulmonary disease (COPD; P=9.3 x 10(-4)), peripheral artery disease (PAD; P=0.090) and abdominal a

80 es were measured in 226 patients with stable peripheral artery disease admitted for nonurgent invasiv

81 Peripheral artery disease affects >200 million people wo

82 Atherosclerotic peripheral artery disease affects 8% to 12% of Americans

83 le disparities in stroke, heart failure, and peripheral artery disease among African Americans.

84 g, adjusted HR 5.76 [4.90-6.77] for incident peripheral artery disease and 10.61 [5.70-19.77] for amp

85 rterial studies investigated lower-extremity peripheral artery disease and acute stroke (35% and 24%,

86 ecently discovered therapeutic treatment for peripheral artery disease and critical limb ischemia.

87 nd organizations to advance the treatment of peripheral artery disease and critical limb ischemia.

88 lpha, improves walking time in patients with peripheral artery disease and intermittent claudication.

89 enase bright (ALDHbr) cells in patients with peripheral artery disease and to explore associated clau

90 Patients with peripheral artery disease are at risk of systemic athero

91 neuroischaemic if peripheral neuropathy and peripheral artery disease are both present.

92 munity-based studies since 1997 that defined peripheral artery disease as an ankle brachial index (AB

93 ents, we analysed adult participants without peripheral artery disease at baseline at the individual

94 sed 817 084 individuals without a history of peripheral artery disease at baseline from 21 cohorts.

95 professionals and millions of patients with peripheral artery disease at the 2015 Centers for Medica

96 anisms underlying the exercise impairment in peripheral artery disease based on an evaluation of the

97 es the first comparison of the prevalence of peripheral artery disease between high-income countries

98 atment of diabetic microvascular disease and peripheral artery disease but are hindered by the comple

99 Future peripheral artery disease cell therapy investigational t

100 In the peripheral artery disease cohort, the primary end point

101 Conclusions and Relevance: Peripheral artery disease confers a poor prognosis in pa

102 The percutaneous therapies for peripheral artery disease continue to evolve with longer

103 Percutaneous therapies for peripheral artery disease continue to evolve with new te

104 red and fifty-five patients with symptomatic peripheral artery disease due to de novo superficial fem

105 ith chronic kidney disease), and at least 50 peripheral artery disease events, we analysed adult part

106 Approximately one-third of patients with peripheral artery disease experience intermittent claudi

107 vascular perfusion is a hallmark feature of peripheral artery disease for which minimal therapeutic

108 May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres.

109 ificantly improved stratification of AAA and peripheral artery disease groups when compared with trad

110 lled based on previous revascularization for peripheral artery disease had higher rates of myocardial

111 In the 21st century, peripheral artery disease has become a global problem.

112 rt-term reproducibility of this technique in peripheral artery disease has not been assessed, and the

113 Patients with peripheral artery disease have a marked reduction in exe

114 Patients with peripheral artery disease have an increased risk of card

115 Preliminary studies of antibiotic therapy in peripheral artery disease have shown a decreased need fo

116 lobally, 202 million people were living with peripheral artery disease in 2010, 69.7% of them in LMIC

117 C), establishes the primary risk factors for peripheral artery disease in these settings, and estimat

118 eview of the literature on the prevalence of peripheral artery disease in which we searched for commu

119 Treatment for symptomatic peripheral artery disease includes lower extremity bypas

120 ceding decade the number of individuals with peripheral artery disease increased by 28.7% in LMIC and

121 Peripheral artery disease is a potentially incapacitatin

122 Lower limb peripheral artery disease is a prevalent chronic non-com

123 These results also suggest that peripheral artery disease is associated with an inflamma

124 oral and popliteal arteries in patients with peripheral artery disease is compromised by restenosis a

125 Peripheral artery disease is considered to be a manifest

126 ents demonstrated among patients with stable peripheral artery disease is elevated after revasculariz

127 Lower extremity peripheral artery disease is the third leading cause of

128 thelial dysfunction present in patients with peripheral artery disease may be better understood by me

129 We then used the risk factors to predict peripheral artery disease numbers in eight WHO regions (

130 Eligible patients had a history of peripheral artery disease of the lower extremities (prev

131 balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial femoral and

132 mia-reperfusion paradigm in 96 patients with peripheral artery disease of varying severity and 10 hea

133 myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb

134 performance and daily ambulatory activity in peripheral artery disease patients with intermittent cla

135 Peripheral artery disease predicted moderate progression

136 nsion, diabetes, cardiovascular disease, and peripheral artery disease predicted severe progression o

137 inergic signaling plays an important role in peripheral artery disease progression.

138 d estimates the number of people living with peripheral artery disease regionally and globally.

139 s without subsequent ST in the Excellence in Peripheral Artery Disease registry.

140 Peripheral artery disease results in atherosclerotic obs

141 data to support use of these therapies after peripheral artery disease revascularization exist, and m

142 Both eGFR and ACR significantly improved peripheral artery disease risk discrimination beyond tra

143 luminal balloon angioplasty in patients with peripheral artery disease Rutherford-Becker class 2 to 5

144 induced ischemia are highly correlated with peripheral artery disease severity.

145 tention should be paid to the development of peripheral artery disease symptoms and signs in people w

146 ificantly lower in patients with symptomatic peripheral artery disease than in healthy volunteers.

147 ication is a common and disabling symptom of peripheral artery disease that can be treated with medic

148 Critical limb ischemia is a manifestation of peripheral artery disease that carries significant morta

149 associated with 15 putative risk factors for peripheral artery disease to estimate their effect size

150 ndomly assigned 111 patients with aortoiliac peripheral artery disease to receive 1 of 3 treatments:

151 ly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ti

152 elor In PAD) randomized 13 885 patients with peripheral artery disease to treatment with ticagrelor 9

153 Evidence from large, randomized, controlled peripheral artery disease trials reporting long-term out

154 trial enrolled 264 patients with symptomatic peripheral artery disease undergoing percutaneous treatm

155 ard ratios (HRs) for incident study-specific peripheral artery disease was 1.22 (95% CI 1.14-1.30) at

156 the adjusted HR for incident study-specific peripheral artery disease was 1.50 (1.41-1.59) at an ACR

157 story of stroke, coronary artery disease, or peripheral artery disease were enrolled in a case-contro

158 patients with claudication and infrainguinal peripheral artery disease were randomized at 9 sites, of

159 butable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:

160 18 261 cases of peripheral artery disease were recorded during follow-up

161 ients with stable coronary artery disease or peripheral artery disease were recruited at 602 hospital

162 with intermittent claudication secondary to peripheral artery disease who were seropositive for C pn

163 In patients with symptomatic peripheral artery disease with a history of limb revascu

164 uality of life for symptomatic patients with peripheral artery disease with intermittent claudication

165 The treatment of peripheral artery disease with percutaneous transluminal

166 ry heart disease, stroke, heart failure, and peripheral artery disease) occurred (236 events in subje

167 tent claudication with objective evidence of peripheral artery disease), of the carotid arteries (pre

168 r disease (myocardial infarction, stroke, or peripheral artery disease).

169 ion functional class, wall motion score, and peripheral artery disease).

170 disease, ischemic stroke, heart failure, and peripheral artery disease).

171 onary heart disease, cerebrovascular events, peripheral artery disease, and congestive heart failure.

172 n and other coronary artery disease, stroke, peripheral artery disease, and congestive heart failure;

173 relative lymphocyte count, prothrombin time, peripheral artery disease, and contralateral carotid occ

174 ia for up to 24 hours in the murine model of peripheral artery disease, and doubled muscle perfusion

175 n off-loading, stimulation of wound healing, peripheral artery disease, and infection.

176 rce, heart failure, coronary artery disease, peripheral artery disease, antiphospholipid syndrome, an

177 , such as myocardial infarction, stroke, and peripheral artery disease, are the leading cause of morb

178 her heart rate, prior myocardial infarction, peripheral artery disease, Asian race, male sex, and hig

179 Older age, shorter height, ischemic cause, peripheral artery disease, atrial fibrillation, diabetes

180 emoral artery of a rat for 72 h, a model for peripheral artery disease, causes an exaggerated exercis

181 chronic lung disease, age 75 years or older, peripheral artery disease, diabetes, tobacco use, white

182 diagnoses (coronary artery disease, stroke, peripheral artery disease, dysrhythmias, or heart failur

183 r V, a man with severe coronary, aortic, and peripheral artery disease, had an episode of brain ische

184 In patients with symptomatic peripheral artery disease, in comparison with LEB, PVI w

185 ncluding hospitalisation with a diagnosis of peripheral artery disease, intermittent claudication, le

186 mb ischemia (CLI), the most advanced form of peripheral artery disease, is associated with significan

187 ary artery disease, cerebrovascular disease, peripheral artery disease, or abdominal aortic aneurysm

188 scular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75

189 scular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75

190 nary artery diseases, heart failure, stroke, peripheral artery disease, or CVD-related mortality.

191 CVD events (coronary heart disease, stroke, peripheral artery disease, or heart failure).

192 ng patients with symptomatic femoropopliteal peripheral artery disease, percutaneous transluminal ang

193 o be older, female, and have higher rates of peripheral artery disease, prior stroke, and hypertensio

194 ry artery disease, congestive heart failure, peripheral artery disease, severe liver disease, diabete

195 proving collateral function in patients with peripheral artery disease, there is currently no method

196 In patients with symptomatic peripheral artery disease, ticagrelor was not shown to b

197 gina, stroke, transient ischemic attack, and peripheral artery disease, were adjudicated by committee

198 disease conferred increased risk of incident peripheral artery disease, with a strong association bet

199 eGFR] and albuminuria) with the incidence of peripheral artery disease.

200 ergic signaling in a cohort of patients with peripheral artery disease.

201 t advance in the management of patients with peripheral artery disease.

202 in improving the outcomes for patients with peripheral artery disease.

203 of patients with symptomatic femoropopliteal peripheral artery disease.

204 pliteal lesions in symptomatic patients with peripheral artery disease.

205 athophysiology of the exercise impairment in peripheral artery disease.

206 l tool to investigate the pathophysiology of peripheral artery disease.

207 dependently associated with the incidence of peripheral artery disease.

208 161 patients with AAA and 168 controls with peripheral artery disease.

209 low in the murine hindlimb ischemia model of peripheral artery disease.

210 to be underused among Medicare patients with peripheral artery disease.

211 nd 2010 to estimate the global prevalence of peripheral artery disease.

212 ding 112,027 participants, of which 9347 had peripheral artery disease.

213 risk for stroke, venous thromboembolism and peripheral artery disease.

214 aseline clinical characteristics, except for peripheral artery disease.

215 re considered as biomarkers for coronary and peripheral artery disease.

216 ance than ST, even for those with aortoiliac peripheral artery disease.

217 ificantly reduced in PACs from patients with peripheral artery disease.

218 nanofibers improves blood flow in a model of peripheral artery disease.

219 ly similar to those displayed by humans with peripheral artery disease.

220 end point among this cohort of patients with peripheral artery disease.

221 ate a symptomatic benefit of this therapy in peripheral artery disease.

222 ak walking time in patients with symptomatic peripheral artery disease.

223 Aging is a risk factor for coronary and peripheral artery disease.

224 omplicated percutaneous revascularization of peripheral artery disease.

225 artery is common in patients suffering from peripheral artery disease.

226 disease is a risk factor for lower-extremity peripheral artery disease.

227 ction seen in rats with ligated arteries and peripheral artery disease.

228 potent antiplatelet agent, in patients with peripheral artery disease.

229 as nonhealing ulcers or gangrene, related to peripheral artery disease.

230 in skeletal muscle biopsies from humans with peripheral artery disease.

231 he most common presentation of infrainguinal peripheral artery disease.

232 rdial infarction, or stroke in patients with peripheral artery disease; however, vorapaxar significan

233 Ischemia, primarily caused by peripheral artery diseases, represents a major complicat

234 etes is a major risk factor for coronary and peripheral artery diseases.

235 ed compensatory responses in 2K1C NSE-AT(1a) peripheral arteries during this later phase, suggest tha

236 d that greater large artery stiffness causes peripheral artery dysfunction; however, a cause-and-effe

237 Testing coronary or peripheral artery endothelial vasomotor dysfunction may

238 In peripheral arteries, expression of a recombinant eNOS ge

239 vidence that EECP has a beneficial effect on peripheral artery flow-mediated dilation and endothelial

240 estigate the extracardiac effects of EECP on peripheral artery flow-mediated dilation.

241 ncreased large artery stiffness and impaired peripheral artery function.

242 and obstruction or incompressibility of the peripheral arteries in RA.

243 (ST), which is a serious adverse outcome of peripheral artery interventions.

244 Calcification of the media of peripheral arteries is referred to as Monckeberg's scler

245 estrogen on atherosclerotic disease in other peripheral arteries is unknown.

246 e about monocytes and their heterogeneity in peripheral artery occlusive disease (PAOD) still is limi

247 However, the effect of ischemic lower limb peripheral arteries on hemodynamics remains unclear.

248 ase, atherosclerotic disease of the aorta or peripheral arteries, or cerebrovascular disease.

249 by the Walking Impairment Questionnaire and Peripheral Artery Questionnaire also improved with both

250 tus was quantified with the disease-specific Peripheral Artery Questionnaire and the generic Short Fo

251 mportant improvement of an 8-point change in Peripheral Artery Questionnaire Summary score after PER

252 Mean Peripheral Artery Questionnaire summary scores improved

253 e with the Walking Impairment Questionnaire, Peripheral Artery Questionnaire, Medical Outcomes Study

254 on, but these changes are less pronounced in peripheral arteries, resulting in stiffness and geometry

255 confidence interval, 0.39-0.86; P=0.006) and peripheral artery revascularization (18.4% versus 22.2%;

256 al infarction; stroke; coronary, carotid, or peripheral artery revascularization; or hospitalization

257 Management of peripheral artery stenosis and occlusion with vascular s

258 Nowadays, imaging diagnostics of peripheral artery stenosis involves non-invasive examina

259 ng in nursing homes, low PPA from central to peripheral arteries strongly predicts mortality and adve

260 and NO bioavailability, was evaluated using peripheral artery tonometry (EndoPAT), and plasma levels

261 (SDF) and endothelial function testing using peripheral artery tonometry are being performed at enrol

262 d NO-dependent endothelial function by using peripheral artery tonometry to determine the reactive hy

263 mmatory markers, vascular function (by using peripheral artery tonometry), and numbers of circulating

264 Aneurysms that involved major peripheral arteries were present in four (13%) of the 31

265 mineralization-regulating proteins in human peripheral arteries with and without MS.

266 re on arterial volume distensibility between peripheral arteries with different compliance.

267 on intraluminal paclitaxel delivery to human peripheral arteries with substantial calcified plaque.

268 ector row CT improved the ability to connect peripheral arteries with their more centrally located pu

269 that include stiff central arteries, normal peripheral arteries with variable pressure amplification

270 vable at multidetector CT angiography of the peripheral arteries without compromising image quality a